1800-272-662
Shopping Cart 0
countryflagAU
Login

Prescient Therapeutics Ltd

Healthcare AU PTX

0.058AUD
0.001(1.75%)

Last update at 2026-03-13T04:49:00Z

Day Range

0.060.06
LowHigh

52 Week Range

0.040.12
LowHigh

Fundamentals

  • Previous Close 0.06
  • Market Cap59.94M
  • Volume768766
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-7.53504M
  • Revenue TTM4.27M
  • Revenue Per Share TTM0.005
  • Gross Profit TTM 4.27M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -7.32253M -11.95000M -7.00450M -5.11718M -4.14882M
Minority interest - - - - -
Net income -7.32253M -8.23800M -7.00450M -5.12371M -5.38205M
Selling general administrative 1.46M 1.49M 3.66M 3.70M 2.93M
Selling and marketing expenses 3.72M 2.43M - - -
Gross profit 4.36M 3.71M - - -
Reconciled depreciation 0.00530M 0.00072M 0.00209M 0.00140M 0.00047M
Ebit -7.53576M -7.18672M -9.88808M -5.11064M -4.13820M
Ebitda -7.53504M -7.18600M -9.88599M -5.10924M -4.13773M
Depreciation and amortization 0.00072M 0.00072M 0.00209M 0.00140M 0.00047M
Non operating income net other - - - - -
Operating income -7.53576M -7.18600M -9.88808M -5.11064M -4.13820M
Other operating expenses 11.89M 10.90M 9.89M 7.10M 5.43M
Interest expense - - - 0.00653M 0.01M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.23M 0.69M 0.46M 0.04M 0.07M
Net interest income 0.23M 0.69M 0.46M 0.04M 0.06M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -4.35640M -3.71200M -0.46119M 0.00653M 1.23M
Total revenue 4.36M 3.71M 0.46M 0.04M 0.07M
Total operating expenses 11.89M 10.90M 9.89M 7.10M 5.43M
Cost of revenue - 0.00072M - - -
Total other income expense net 0.21M -4.76400M 2.42M -0.00653M -0.01061M
Discontinued operations - - - - -
Net income from continuing ops -7.32253M -8.23805M -7.00450M -5.11718M -4.14882M
Net income applicable to common shares -7.32253M -8.23805M -7.00450M -5.11718M -4.14882M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 14.56M 20.39M 28.11M 17.62M 20.97M
Intangible assets 1.65M 1.65M 3.37M 3.37M 3.37M
Earning assets - - - - -
Other current assets 4.65M 0.31M 2.37M 1.64M 1.19M
Total liab 3.17M 2.33M 2.03M 0.86M 0.54M
Total stockholder equity 11.39M 18.07M 26.08M 16.76M 20.43M
Deferred long term liab - - - - -
Other current liab - 0.27M 0.25M 0.30M 0.28M
Common stock - 93.27M 93.25M 77.26M 76.67M
Capital stock 93.89M 93.27M 93.25M 77.26M 76.67M
Retained earnings -84.06704M -77.39700M -69.31332M -62.45208M -57.50762M
Other liab - - 0.00622M 0.05M 0.03M
Good will - - - - -
Other assets - 0.00000M - - -
Cash 6.91M 10.49M 5.90M 12.26M 16.10M
Cash and equivalents - - 4.00M - -
Total current liabilities 3.16M 2.32M 2.03M 0.81M 0.51M
Current deferred revenue - - - - -0.16583M
Net debt - -10.16270M -5.89543M -12.26384M -15.93168M
Short term debt - 0.33M 0.00000M 0.00000M 0.17M
Short long term debt - 0.33M - - 0.17M
Short long term debt total - 0.33M - - 0.17M
Other stockholder equity - - -23.93308M -14.81218M -19.16355M
Property plant equipment - - 0.00282M 0.00490M 0.00188M
Total current assets 12.90M 18.74M 24.74M 14.25M 17.60M
Long term investments - - - - -
Net tangible assets - - 22.71M 13.40M 17.06M
Short term investments 0.02M 4.02M 16.02M 0.02M 0.02M
Net receivables 0.26M 3.92M 0.21M 0.08M 0.05M
Long term debt - - - - -
Inventory - - 0.25M 0.24M 0.24M
Accounts payable 3.04M 1.72M 1.78M 0.51M 0.23M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 2.19M 2.14M 1.95M 1.26M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -0.00000M -3.36971M -3.37180M -3.36877M
Deferred long term asset charges - - - - -
Non current assets total 1.66M 1.65M 3.37M 3.37M 3.37M
Capital lease obligations - - - - -
Long term debt total - - 0.00000M 0.00000M 0.00000M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments 4.00M 12.00M -16.00000M -0.00443M -0.00231M
Change to liabilities - - 1.16M 0.39M -0.38523M
Total cashflows from investing activities 4.00M 12.00M -16.00000M -0.00443M -0.00231M
Net borrowings -0.33049M - - -0.16583M 0.00895M
Total cash from financing activities -0.33049M 0.02M 15.83M 0.43M 12.75M
Change to operating activities - - -0.68720M -0.38777M -0.09677M
Net income -7.32253M -8.23805M -7.00450M -5.11718M -4.14882M
Change in cash -3.58638M 4.60M -6.36841M -3.83367M 8.74M
Begin period cash flow 10.49M 5.90M 12.26M 16.10M 7.36M
End period cash flow 6.91M 10.49M 5.90M 12.26M 16.10M
Total cash from operating activities -7.24351M -7.39791M -6.19100M -4.31266M -3.97003M
Issuance of capital stock - 0.02M 16.53M 0.59M 13.58M
Depreciation - 0.00072M 0.00209M 0.00140M 0.00047M
Other cashflows from investing activities 4.00M 12.00M - - -
Dividends paid - - - - 12.75M
Change to inventory - - - - -
Change to account receivables 0.54M -1.34112M -0.13106M -0.02400M -0.02387M
Sale purchase of stock 0.00000M 0.02M - 0.59M -0.83655M
Other cashflows from financing activities - -0.01815M -0.69782M -0.00443M 12.77M
Change to netincome - - 0.47M 0.83M 0.68M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00443M 0.00231M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.05M -1.11152M -0.13106M -0.02400M -0.02387M
Stock based compensation - 0.21M 0.46M 0.88M 0.65M
Other non cash items -7.29692M 1.95M 0.81M 0.80M 0.18M
Free cash flow -7.24351M -7.39791M -6.19100M -4.31709M -3.97234M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
PTX
Prescient Therapeutics Ltd		 0.001 1.75% 0.06 - 5.48 14.05 3.59 -8.358
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

Prescient Therapeutics Ltd

Suite 2, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Mr. Steven Lee Yatomi-Clarke MD, CEO & Director NA
Ms. Melanie Jaye Leydin B.Bus, C.A., CA CFO & Company Sec. 1973
Ms. Leanne West Director of Clinical Affairs & Operations NA
Dr. Terrence G. Chew Chief Medical Officer 1947
Ms. Rebecca Lim Sr. VP of Scientific Affairs NA
Ms. Melanie Jaye Leydin B.Bus, C.A. CFO & Company Secretary 1973
Ms. Melanie Jaye Leydin B.Bus, C.A. CFO & Company Secretary 1973
Ms. Rebecca Lim Senior Vice President of Scientific Affairs NA
Ms. Melanie Jaye Leydin B.Bus, C.A. CFO & Company Secretary 1973
Ms. Rebecca Lim Senior Vice President of Scientific Affairs NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.